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Table 1. HSCT outcomes in children with hypodiploid ALL at 5 years
DFS % (range) OS % (range) Relapse% (range) TRM% (range)
<———————————————————————5 year estimates———————————————————————>
All patients 51 (40-62) 56 (44-67) 27 (18-38) 22 (14-32)
Patients in CR1 55 (40-70) 58 (43-72) 26 (14-40) 20 (9-33)
CR1 patients with 43 chromosomes 47 (29-66) 50 (32-69) 30 (15-47) 23 (9-41)
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calculate overall survival (OS) and cumulative incidence
methods for secondary outcomes, including neutrophil and
platelet engraftment, incidence of graft-versus-host disease
(GvHD) and disease-speciﬁc characteristics at most recent
follow-up. The two-sided log-rank test was used for univar-
iate comparisons.
Seventy patients (31 ALD, 5 Krabbe, 34 MLD) were available
for analysis, with a median age at transplant of 6.5 years.
Median follow-up for survivors was 46 months. OS at 4 years
was 60% (6%). Cumulative incidences of neutrophil and
platelet engraftment were 88% (4%) at day 60, and 73%
(6%) at day 180, resp. Acute-GvHD (grade II-IV) occurred in
16 patients (22% 5%) at day 100 and chronic-GvHD in 9
patients (13%5%). Out of the 24 patients who died, 18 (67%)
died of transplant-related causes and 6 (33%) died of disease
progression. Higher OS was seen in patients who had no or 1
HLA mismatch (OS 81%), compared to patients who received
a CBT with 2 HLA mismatches (OS 47%, p 0.02).
On 37 patients (53%), information on disease-speciﬁc char-
acteristics was available. OS among these patients was 68%
(8), which was not signiﬁcantly different from patients
without disease-speciﬁc information (p¼0,307). Nineteen
patients (51%) were asymptomatic at transplant, 14 (38%)
had mild disease and 4 (11%) were severely affected. Overall
survival was worse in patients with severe disease at trans-
plant; none of these 4 patients survived, versus 79% of mildly
affected and 76% of asymptomatic patients. At most recent
follow-up, disease status was stable in 15 (57.7%), had
improved in 2 (7.7%) and worsened in 9 (34.6%) surviving
patients. The majority of patients showed abnormalities on
MRI-scanning pre-HSCT (n¼25, 68%). In patients with
normal MRI-scans pre-transplant OS was 69%; in patients
with abnormal MRI-scans 75%.
In conclusion, we found an encouraging OS of 60% at 4 years,
with relatively low rates of GvHD. Use of a mismatched
donor (>1 HLA) negatively impacts survival. Data on clinical
characteristics suggest that OS is strongly inﬂuenced by
disease status at transplant.97
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Petersburg, FLChildren with hypodiploid ALL have inferior outcomes with
chemotherapy despite intensive risk adapted treatment. A
case series of pediatric hypodiploid ALL (n¼139) with <45
chromosomes treated by 10 different national ALL study
groups (Nachman et al; 2007), reported an 8-year event free
survival (EFS) of 38.5% and overall survival (OS) of 49.8%.
Patients with fewer than 44 chromosomes fared signiﬁcantly
worse than those with 44 chromosomes (EFS of 30% vs. 52%,
p¼0.01). A similar report from the Medical Research Council
(MRC) included 226 children and adults treated with
chemotherapy (Harrison et al, 2004). Patients with 42-45
chromosomes (n¼153) had a 3 year survival of 66%
compared to 29% in those with 25-39 chromosomes.
We conducted a retrospective study of 78 children with hy-
podiploid ALL who underwent HSCT between 1990 and 2010
and reported to CIBMTR, to determine whether outcomes
might be improved with transplant.
Median age at HSCT was 10 years (range 3-18). Thirty nine
(50%) patients had  43 chromosomes, 12 (15%) had 44
chromosomes and 27 (35%) had 45 chromosomes. Forty
three (55%) patients were transplanted in CR1while 35 (45%)
were transplanted in CR2. Twenty nine patients (37%)
received a graft from a related donor, 34 (44%) an unrelated
donor and 15 (19%) cord blood. Demographics and transplant
characteristics were similar in those with chromosomes 43
or44 and those transplanted with early or late disease (CR1
or CR2 and beyond). All patients received a myeloablative
conditioning regimen.
Multivariate analysis conﬁrmed both disease status and
number of chromosomes were independently associated
with mortality; mortality risks were higher for transplants in
CR2 (HR 2.16, p¼0.05) and when chromosomes were <¼43
(HR 2.15, p¼0.05).The 5-year estimates of DFS, OS, relapse,
and treatment related mortality (TRM) for the entire group,
those in CR1 and for those in CR1with43 chromosomes are
shown in Table 1. In the group with 44 chromosomes
(n¼13), 3 patients died and 10 were alive at last contact (9
disease free and 1 with relapsed disease). Despite the
obvious limitation of small numbers of patients and the
retrospective nature of our study, our results suggest that
compared to historical results from chemotherapy only
treatment, pediatric patients with hypodiploid ALL, may
have improved outcomes when transplanted in CR1, and
beneﬁt may be most notable in those with 43 chromo-
somes.98
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Table
Characteristics N ¼12
Disease e N (%) Krabbe Disease 3 (25%)
MHC II Deﬁciency 2 (17%)
Metachromatic Leukodystrophy 1 (8%)
Hunter Syndrome 1 (8%)
Diamond-Blackfan Anemia 1 (8%)
Cartilage-Hair Hypoplasia 1 (8%)
Combined Immunodeﬁciency 1 (8%)
HLH 1 (8%)
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Background: The use of 4/6 matched cord blood units in-
creases access to hematopoietic stem cell transplantation
particularly for racial and ethnic minority patients. We con-
ducted an analysis to identify factors that favor longer term
survival in patients transplanted with single 4/6 matched
cord blood (CB) grafts after myeloablative conditioning at a
single center.
Methods: We retrospectively reviewed all consecutive single
CB transplants in patients ages <21 years using a myeloa-
blative regimen from 08/1993-04/2012 at Duke using 4/6
matched (low-res HLA-A and B; high-res DRB1) unrelated
donors. Prognostic factors were assessed in univariate KM
analyses of overall survival (OS), disease free survival (DFS)
and cumulative incidence (CInc) of neutrophil and platelet
engraftment, acute grades III-IV graft-versus-host disease
(GVHD) and chronic GVHD. Cox proportional hazards models
were constructed using backward selection. P-values <0.05
were considered statistically signiﬁcant inmultivariatemodel.
Results: 365 patients (68% Caucasian. 62.5% CMV+) with a
median age of 6.28 years with malignant (MAL, n¼208) and
non-malignant (nMAL, n¼157) diagnoses were identiﬁed
with a median follow-up of 10.9 years (range, 1.4-19.9 years).
Median cell dose was 6.3x10e7/kg overall and was higher in
the nMAL group (8.47) which included younger children. The
CInc of neutrophil engraftment was 77.9%, 80% and 75.2% and
platelet engraftment was 54.2%, 51.2% and 58.2% for the total,
MAL and nMAL cohorts, respectively. Graft failure or autol-
ogous recovery occurred in 24 (6.6%) and 12 (3.3%) patients.
The probability of OS at 1, 5, 10 and 15 years was 57.3%, 47.6%,
46.2% and 46.2% in all patients and did not differ signiﬁcantly
for the MAL and nMAL cohorts. The probability of DFS at 1, 5,
10 and 15 years in the MAL cohort was 47.6%, 42.2%, 41.7%
and 41.7%. The CInc of acute GVHD grades III-IV by 100 days
was 14% and of chronic GVHD was 13.7% at 1 and 18.2% at 2
years. On multivariate analysis, OS in all patients and DFS in
MAL cohort was favorably impacted by recipient CMV sero-
negativity and a cell dose of >2.5x10e7/kg measured on the
pre-cryopreservation graft. In the MAL cohort, DFS was bet-
ter in recipients of a gender mismatched graft and HLA
matching. In the nMAL cohort, a cell dose >6.62x10e7/kg
was associated with higher OS. Engraftment was better in
recipients of higher cell dose grafts and in donor/recipient
pairs matched at HLA-B. Acute GVHD was higher in black
recipients overall, and higher when the donor/recipient pairs
were not matched for race.
Conclusions: 4/6 matched UCBT is an effective treatment for
children with MAL and nMAL diseases leading to long term
survival. Impact of cell dose, race, gender and differential
HLA matching will improve donor selection. These outcomes
are similar to those reported with better matched UCB grafts
and support the use of 4/6 UCBT for patients lacking a closer
matched donor.Osteopetrosis 1 (8%)
Donor Match e N (%) 6/6 5 (42%)
5/6 3 (25%)
4/6 4 (33%)
Acute GVHD - N (%) Grade I 2 (17%)
Grade II 2 (17%)
Grade III-IV 1 (8%)
GVHD Target Organ - N (%) Skin 4 (33%)
GI 2 (17%)99
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PAReduced-intensity conditioning (RIC) regimens have been
shown to decrease transplant-related morbidity and mor-
tality; however, this comes with an increased risk of
graft failure and morbidity/mortality secondary to in-
fections following intense serotherapy. Here we report on a
novel RIC conditioning regimen for chemotherapy naïve
children.
Between 2012 and 2013, 12 consecutive patients (median
age 1 year, range: 0.5-14 years) underwent single unit
umbilical cord blood transplantation (UCBT) at the Chil-
dren’s Hospital of Pittsburgh (Table). Patients received
alemtuzumab (1.2-2.2 mg/kg), hydroxyurea (30 mg/kg/
day), ﬂudarabine (150 mg/m2), melphalan (140 mg/m2),
and thiotepa (200 mg/m2), with tacrolimus and mycophe-
nolate as GVHD prophylaxis. Most patients received an
HLA-mismatched unit. The median cell dose was 8.6 x107
(range: 3.8-11.0 x107) TNC/kg and 2.55 x105 (range 1.55-
6.17 x105) CD34+ cells/kg.
Neutrophil engraftment was rapid, and occurred in all
patients at a median of 15.5 days post-UCBT (range: 12-
31). Platelet engraftment (>50K) occurred at a median of
40.5 days post-UCBT (range 32-63). 11 of 12 patients had
>98% donor whole blood chimerism at ﬁrst measurement,
performed at a median of 30 days post-UCBT. The median
chimerism was 100% in whole blood (range: 89-100%) and
T cell fraction (range 95-100%) at 6 months post-UCBT
(n¼7), and 96% (range: 85-100%) in whole blood and 91%
(range 76-100%) in the T cell fraction at 12 months (n¼5).
In a limited sample of patients, TREC number and TCR Vb
repertoire achieved pre-transplant values by 9 months
post-UCBT (Figure). 5 patients (42%) developed viremia
with CMV (n¼2), adenovirus (n¼1), EBV (n¼2), or HHV-6
(n¼3); however, no patients developed end-organ disease.
The incidence of acute GVHD was low, with 25% of pa-
tients developing grade II-IV acute GVHD, and only one
with grade III acute GVHD. All patients responded to
therapy. None of the 9 patients who are beyond Day
180 post-UCBT have developed extensive chronic GVHD.
5 of the 6 patients evaluable at 1 year post-UCBT are
completely off systemic immunosuppression. All patients
are alive with a median follow-up of 11 months (range 3-
25 months).
In conclusion, this novel RIC regimen allows for rapid
engraftment of donor cells and immune reconstitution with
acceptable rates of viral reactivation and GVHD.
